Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555282 | 0.98 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL5557209 | 0.84 | BACE1 (0.39) | ALDH1A1KDM4EPOLBL3MBTL1TDP1 | |
| SCHEMBL5551517 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL5555219 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL5557277 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL8560245 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KDM4EPOLBL3MBTL1USP2 | |
| SCHEMBL5555275 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL8482735 | 0.77 | TEAD3 (0.43) | ALDH1A1POLBL3MBTL1TSHRMEN1 | |
| SCHEMBL5555359 | 0.77 | ALDH1A1 (0.41) | ALDH1A1KDM4EPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL5555201 | 0.76 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBL3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208139-B2 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | SCHERING AG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-6855309-B2 | For use in diagnostics and therapy | SCHERING, AG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030232017-A1 | For use in diagnostics and therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6576222-B2 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-10 | — | — | US | disclosed |
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6299859-B1 | ADMINISTERING CONTRAST AGENT COMPRISING CASCADE POLYMER COMPLEX AND NUCLEAR MAGNETIC RESONANCE IMAGING TISSUES FOR DIFFERENTIATING ISCHEMIC AND/OR INFRACTED TISSUE FROM NORMAL TISSUES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-09 | — | — | US | disclosed |
| US-6193950-B1 | FOR DIAGNOSIS AND THERAPY | SCHERING AG (DE) | 2001-02-27 | — | — | US | disclosed |
| US-6183724-B1 | ADMINISTERING A CONTRAST AGENT FOR NMR IMAGING THE BLOOD VESSELS, SIZE LARGE ENOUGH FOR ITS RETENTION IN THE BLOOD VESSELS AND SMALL ENOUGH FOR ITS EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-06 | — | — | US | disclosed |
| US-6054117-A | NUCLEAR MAGNETIC RESONANCE CONTRAST MEDIA FOR DIAGNOSTICS AND THERAPY; PHYSIOLOGICALLY ACCEPTABLE EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| EP-0430863-B2 | Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same | SCHERING AG (DE) | 1999-08-25 | — | — | EP | disclosed |
| US-5911971-A | NMR CONTRAST MEDIA WHICH CAN MARK THE VASAL SPACE (BLOOD POOL AGENT); UNIFORM AND HIGH ENOUGH MOLECULAR WEIGHT TO BE RETAINED IN BLOOD VESSEL BUT SMALL ENOUGH TO BE ELIMINATED BY THE KIDNEY; POLYAMINOAMIDES; MACROMOLECULES | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-15 | — | — | US | disclosed |
| US-5876698-A | Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | disclosed |
| EP-0512661-B1 | Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them | SCHERING AG (DE) | 1998-01-14 | — | — | EP | disclosed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| US-5364614-A | Cascade polymer bound chelating compounds, their chelates and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| EP-0512661-A1 | Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0430863-A2 | Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | CAD, APOB, SLC7A1 | ALDH1A1 4841/4885KDM4E 4688/4885POLB 687/4885 |
| US-20030232017-A1 | For use in diagnostics and therapy | TFPI, BCAT2, OAT | ALDH1A1 3976/4885KDM4E 4762/4885POLB 163/4885 |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | FABP7, SLC1A3, SLC43A1 | ALDH1A1 4833/4885KDM4E 4731/4885POLB 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.